Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Kiora Pharmaceuticals (KPRX) EPS (Weighted Average and Diluted) (2018 - 2025)

Kiora Pharmaceuticals' EPS (Weighted Average and Diluted) history spans 8 years, with the latest figure at -$1.6 for Q4 2025.

  • For Q4 2025, EPS (Weighted Average and Diluted) fell 53.85% year-over-year to -$1.6; the TTM value through Dec 2025 reached -$2.65, down 345.37%, while the annual FY2025 figure was -$2.64, 403.45% down from the prior year.
  • EPS (Weighted Average and Diluted) reached -$1.6 in Q4 2025 per KPRX's latest filing, down from $0.01 in the prior quarter.
  • In the past five years, EPS (Weighted Average and Diluted) ranged from a high of $3.46 in Q1 2024 to a low of -$21.43 in Q4 2021.
  • Average EPS (Weighted Average and Diluted) over 5 years is -$3.63, with a median of -$0.9 recorded in 2023.
  • Peak YoY movement for EPS (Weighted Average and Diluted): crashed 8829.17% in 2021, then soared 446.0% in 2024.
  • A 5-year view of EPS (Weighted Average and Diluted) shows it stood at -$21.43 in 2021, then skyrocketed by 71.86% to -$6.03 in 2022, then soared by 85.07% to -$0.9 in 2023, then fell by 15.56% to -$1.04 in 2024, then plummeted by 53.85% to -$1.6 in 2025.
  • Per Business Quant, the three most recent readings for KPRX's EPS (Weighted Average and Diluted) are -$1.6 (Q4 2025), $0.01 (Q3 2025), and -$0.54 (Q2 2025).